Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.

  • Ulrich Klotz
  • Published 2006 in
    International journal of clinical pharmacology…

Abstract

Proton pump inhibitors (e.g. omeprazole/esomeprazole, lansoprazole, pantoprazole, rabeprazole) have a prominent role in the short- and long-term management of acid-related intestinal disease. They are eliminated by the hepatic route and the polymorphic CYP2C19 is involved in their metabolism. Three phenotypes have been identified in various populations… (More)

Topics

Cite this paper

@article{Klotz2006ClinicalIO, title={Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.}, author={Ulrich Klotz}, journal={International journal of clinical pharmacology and therapeutics}, year={2006}, volume={44 7}, pages={297-302} }